Until now, there are biologics in four different classes (anti-TNF-α, anti-IL-17, antiIL-12/IL-23p40, and anti-IL-23p19) have been approved for the treatment of moderate-to-severe psoriasis (8). Here, IL17A is linked to psoriasis.